AU2020330424A1 - Topical composition comprising a prostaglandin analogue - Google Patents

Topical composition comprising a prostaglandin analogue Download PDF

Info

Publication number
AU2020330424A1
AU2020330424A1 AU2020330424A AU2020330424A AU2020330424A1 AU 2020330424 A1 AU2020330424 A1 AU 2020330424A1 AU 2020330424 A AU2020330424 A AU 2020330424A AU 2020330424 A AU2020330424 A AU 2020330424A AU 2020330424 A1 AU2020330424 A1 AU 2020330424A1
Authority
AU
Australia
Prior art keywords
composition
latanoprost
hair
skin
semifluorinated alkane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020330424A
Other languages
English (en)
Inventor
Bernhard Hauptmeier
Frank LÖSCHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermaliq Therapeutics Inc
Original Assignee
Dermaliq Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermaliq Therapeutics Inc filed Critical Dermaliq Therapeutics Inc
Publication of AU2020330424A1 publication Critical patent/AU2020330424A1/en
Assigned to DERMALIQ THERAPEUTICS, INC. reassignment DERMALIQ THERAPEUTICS, INC. Request for Assignment Assignors: NOVALIQ GMBH
Priority to AU2026202586A priority Critical patent/AU2026202586A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020330424A 2019-08-09 2020-08-06 Topical composition comprising a prostaglandin analogue Abandoned AU2020330424A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026202586A AU2026202586A1 (en) 2019-08-09 2026-04-07 Topical composition comprising a prostaglandin analogue

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19191035.5 2019-08-09
EP19191035 2019-08-09
PCT/EP2020/072211 WO2021028328A1 (en) 2019-08-09 2020-08-06 Topical composition comprising a prostaglandin analogue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026202586A Division AU2026202586A1 (en) 2019-08-09 2026-04-07 Topical composition comprising a prostaglandin analogue

Publications (1)

Publication Number Publication Date
AU2020330424A1 true AU2020330424A1 (en) 2022-03-03

Family

ID=67587648

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020330424A Abandoned AU2020330424A1 (en) 2019-08-09 2020-08-06 Topical composition comprising a prostaglandin analogue
AU2026202586A Pending AU2026202586A1 (en) 2019-08-09 2026-04-07 Topical composition comprising a prostaglandin analogue

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026202586A Pending AU2026202586A1 (en) 2019-08-09 2026-04-07 Topical composition comprising a prostaglandin analogue

Country Status (8)

Country Link
US (2) US20220362382A1 (https=)
EP (1) EP4009952A1 (https=)
JP (2) JP2022543402A (https=)
KR (1) KR20220044739A (https=)
CN (1) CN114206344A (https=)
AU (2) AU2020330424A1 (https=)
CA (1) CA3144193A1 (https=)
WO (1) WO2021028328A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2714010T3 (en) 2011-05-25 2017-06-12 Novaliq Gmbh TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORED ALKANES
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
EP4374851B1 (en) 2016-12-23 2026-04-15 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
SG11202007860XA (en) 2018-03-28 2020-09-29 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
KR20220058577A (ko) 2019-09-06 2022-05-09 노바리크 게엠베하 포도막염 치료를 위한 안과용 조성물
WO2025133899A1 (en) 2023-12-19 2025-06-26 Glenmark Specialty S.A. Topical composition comprising dutasteride and latanoprost for alopecia
WO2025149998A1 (en) * 2024-01-11 2025-07-17 Glenmark Specialty S.A. Topical composition comprising clascoterone and latanoprost for alopecia
WO2026013128A1 (en) * 2024-07-10 2026-01-15 Dermaliq Therapeutics, Inc. Treatment of androgenetic alopecia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1021179B1 (en) * 1997-02-04 2004-05-12 Murray A. Johnstone Method of enhancing hair growth
JP2005225817A (ja) * 2004-02-13 2005-08-25 Jiyugaoka Clinic 睫毛用育毛剤
DK2498783T3 (en) * 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
US9149484B2 (en) * 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
PL2547323T3 (pl) * 2010-03-17 2016-07-29 Novaliq Gmbh Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
JP6023181B2 (ja) * 2011-05-25 2016-11-09 ノバリック ゲーエムベーハー 爪に投与するための医薬組成物
WO2013106565A1 (en) 2012-01-10 2013-07-18 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide f2 alpha agonists
EP2944324A1 (de) * 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
PT3442480T (pt) * 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
MX2020003534A (es) * 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.

Also Published As

Publication number Publication date
JP2022543402A (ja) 2022-10-12
AU2026202586A1 (en) 2026-04-23
US20260041773A1 (en) 2026-02-12
CA3144193A1 (en) 2021-02-18
JP2025160428A (ja) 2025-10-22
US20220362382A1 (en) 2022-11-17
CN114206344A (zh) 2022-03-18
EP4009952A1 (en) 2022-06-15
WO2021028328A1 (en) 2021-02-18
KR20220044739A (ko) 2022-04-11

Similar Documents

Publication Publication Date Title
US20260041773A1 (en) Topical composition comprising a prostaglandin analogue
RU2567792C2 (ru) Композиции и способы стимулирования роста волос
RU2703713C2 (ru) Композиции для местного нанесения, содержащие биматопрост, и способы стимуляции роста волос с их помощью
US9149484B2 (en) Compositions and methods for stimulating hair growth
US11696915B2 (en) Methods and compositions for the treatment of hair loss
US9248167B2 (en) Exfoliative hair retention-promoting formulation
CA3198046A1 (en) Compositions and methods for deep dermal drug delivery
JP3981074B2 (ja) オルニチンデカルボキシラーゼインヒビターの毛包輸送のための局所用組成物
MXPA06004407A (es) Reduccion de crecimiento de vello al aplicar un agonista del receptor dp de prostaglandina.
US20250325545A1 (en) Methods and compositions for the treatment of hair loss
US20040141935A1 (en) Reduction of hair growth
EP1928481A2 (en) Novel skin care compositions
KR20260055529A (ko) 국소 조성물
CN101087583A (zh) 用生存素抑制剂来减少毛发生长
CA3193642A1 (en) Compositions and methods for the treatment of hair loss and other conditions
WO2026013128A1 (en) Treatment of androgenetic alopecia
AU2024243786A1 (en) Clascoterone and minoxidil combination therapy for use in treating hair loss
UA118835C2 (uk) Композиція і спосіб стимулювання росту волосся

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DERMALIQ THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): NOVALIQ GMBH